Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

This publication has 37 references indexed in Scilit:

• Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy
  Journal of the Society for Gynecologic Investigation, 2003
• Detection of Insulin Resistance by Simple Quantitative Insulin Sensitivity Check Index QUICKI for Epidemiological Assessment and Prevention
  Journal of Clinical Endocrinology & Metabolism, 2002
• Clinical Significance of the Insulin Resistance Index as Assessed by Homeostasis Model Assessment.
  Endocrine Journal, 2001
• Rosiglitazone
  Drugs, 1999
• Pathogenesis of Type 2 Diabetes
  Drugs, 1999
• Pharmacological Modulation of Insulin Resistance and Hyperinsulinemia in Polycystic Ovary Syndrome
  The Endocrinologist, 1998
• Intraovarian Regulation: The Proposed Role of Insulin-like Growth Factors
  Annals of the New York Academy of Sciences, 1993
• Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
  Clinical Endocrinology, 1992
• Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome
  The Lancet, 1990
• Hyperinsulinemia in a Population at High Risk for Non-Insulin-Dependent Diabetes Mellitus
  New England Journal of Medicine, 1986